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Summary
Background A systematic understanding of how multimorbidity has been constructed and measured is unavailable. This 
review aimed to examine the definition and measurement of multimorbidity in peer-reviewed studies internationally.
Methods We systematically reviewed studies on multimorbidity, via a search of nine bibliographic databases (Ovid 
[PsycINFO, Embase, Global Health, and MEDLINE], Web of Science, the Cochrane Library, CINAHL Plus, Scopus, 
and ProQuest Dissertations & Theses Global), from inception to Jan 21, 2020. Reference lists and tracked citations of 
retrieved articles were hand-searched. Eligible studies were full-text articles measuring multimorbidity for any 
purpose in community, primary care, care home, or hospital populations receiving a non-specialist service. Abstracts, 
qualitative research, and case series were excluded. Two reviewers independently reviewed the retrieved studies with 
conflicts resolved by discussion or a third reviewer, and a single researcher extracted data from published papers. To 
assess our objectives of how multimorbidity has been measured and examine variation in the chronic conditions 
included (in terms of number and type), we used descriptive analysis (frequencies, cross-tabulation, and negative 
binomial regression) to summarise the characteristics of multimorbidity studies and measures (study setting, source 
of morbidity data, study population, primary study purpose, and multimorbidity measure type). This systematic 
review is registered with PROSPERO, CRD420201724090.
Findings 566 studies were included in our review, of which 206 (36·4%) did not report a reference definition for 
multimorbidity and 73 (12·9%) did not report the conditions their measure included. The number of conditions 
included in measures ranged from two to 285 (median 17 [IQR 11–23). 452 (79·9%) studies reported types of condition 
within a single multimorbidity measure; most included at least one cardiovascular condition (441 [97·6%] of 452 studies), 
metabolic and endocrine condition (440 [97·3%]), respiratory condition (422 [93·4%]), musculoskeletal condition 
(396 [87·6%]), or mental health condition (355 [78·5%]) in their measure of multimorbidity. Chronic infections 
(123 [27·2%]), haematological conditions (110 [24·3%]), ear, nose, and throat conditions (107 [23·7%]), skin conditions 
(70 [15·5%]), oral conditions (19 [4·2%]), and congenital conditions (14 [3·1%]) were uncommonly included. Only 
eight individual conditions were included by more than half of studies in the multimorbidity measure used (diabetes, 
stroke, cancer, chronic obstructive pulmonary disease, hypertension, coronary heart disease, chronic kidney disease, 
and heart failure), with individual mental health conditions under-represented. Of the 566 studies, 419 were rated to be 
of moderate risk of bias, 107 of high risk of bias, and 40 of low risk of bias according to the Effective Public Health 
Practice Project quality assessment tool.
Interpretation Measurement of multimorbidity is poorly reported and highly variable. Consistent reporting of 
measure definitions should be required by journals, and consensus studies are needed to define core and 
study-dependent conditions to include in measures of multimorbidity.
Funding Health Data Research UK.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Due to increasing longevity and improved survival from 
acute conditions, the number of people living with mul­
tiple long­term health conditions is rising.1 In 2018, the UK 
Academy of Medical Sciences defined multimorbidity as 
the coexistence of two or more chronic health conditions 
in an individual, any one of which should be a long­term 
physical non­communicable disease, a mental health con­
dition of long duration, or a long­term infectious disease.2 
Multimorbidity differs conceptually from comorbidity, for 
which the focus is on any additional conditions that people 
with a specified index condition also have.3 Recognition is 
growing that existing health­care systems are seriously 
challenged by multimorbidity because they are largely 
designed to care for patients with single conditions, and 
multimorbidity is being increasingly researched.4,5
Despite the growing interest in multimorbidity, how 
it is defined and measured varies substantially. Several 
studies have examined the definition and measurement 
of multi morbidity.6 Although there is agreement that 
multimorbidity is common and often burdensome, vary ing 
operational definitions of multimorbidity are recog nised to 
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have led to heterogeneous estimates of multi morbidity 
prevalence and burden.6–9 Operational definitions differ 
in terms of the number and types of conditions included, 
the cutoff number of conditions for defining when 
multimorbidity is present, whether condi tions are simply 
counted or are weighted in relation to predefined outcomes, 
and the data sources and data collection methods used.6,8,10–13 
Therefore, no clear consen sus exists on how to measure 
multimorbidity, nor on which conditions to include in a 
measure.6,7,14 This lack of consensus makes comparison 
across research studies difficult because the underlying 
measure used by each study can be very different.
The aim of this systematic review was to examine 
how multimorbidity has been measured in peer­reviewed 
studies internationally, including which chronic con­




We systematically reviewed studies measuring multi­
morbidity, and examined the design and characteristics 
of multimorbidity measures used. The review proto­
col was registered with PROSPERO (CRD42020172409). 
This paper reports findings relating to the first 
two registered objectives, of how multimorbidity has 
been measured and variation in the chronic conditions 
included (in terms of type and number). Findings for the 
third registered objective, to identify factors associated 
with heterogeneity of estimated multi morbidity prev­
alence, were based on different analytical approaches 
and will be reported separately.
We followed the CoCoPop mnemonic (Condition, 
Context, and Population) for systematic reviews of obser­
va tional studies to define eligibility criteria and conduct 
searches.15 The condition focused on in the review was 
multimorbidity, for which we did not require alignment to 
any particular definition of multimorbidity but rather 
explored whether studies explicitly stated or justified their 
underlying definition of it. In terms of context and 
population, we examined studies in community, primary 
care, care home, or hospital settings. Other inclusion 
criteria were that studies had full text of the study report 
available and were reported in English. We excluded 
studies that did not measure multimorbidity (eg, were 
comorbidity studies), that focused on people within a 
specialist service such as critical care, or in which the 
morbidity measurement focused on acute conditions or 
Research in context
Evidence before this study
To identify studies relevant to multimorbidity measurement, 
we used two key terms (multimorbidity AND measurement) to 
search Ovid (PsycINFO, Embase, Global Health, and MEDLINE), 
Web of Science, the Cochrane Library, CINAHL Plus, Scopus, 
and ProQuest Dissertations & Theses Global, from database 
inception to Jan 21, 2020, for English-language studies. 
Previous narrative systematic reviews examining 
multimorbidity measure design concluded that the number and 
type of conditions included in multimorbidity counts varies, 
but these reviews only included small numbers of studies with 
incomplete searching. Other reviews examined the 
performance of weighted indices in predicting one or more 
outcomes, concluding that the Charlson comorbidity index and 
Elixhauser’s comorbidity index had high predictive performance 
for mortality, the health-related quality of life comorbidity 
index for quality of life, Bayliss’ weighted index for physical 
functioning and self-rated health, and the Johns Hopkins 
Adjusted Clinical Groups system and medication-based indices 
for health-care use and costs. However, differences in predictive 
performance between measures (including between weighted 
indices and simple counts of conditions) were small.
Added value of this study
This systematic review is, to our knowledge, the largest to date, 
and systematically examines variation in the reporting and 
measurement of multimorbidity. The present analysis identifies 
considerable variation in how multimorbidity is measured in 
the research literature, particularly in relation to the number 
and type of conditions included in different studies. Reporting 
was often poor, with one in eight studies not reporting which 
conditions were included in their multimorbidity measure. 
We found large variation in the number of conditions included 
in multimorbidity measures (range 2 to 285 conditions), 
and which conditions were included. Only eight conditions 
were included by more than half of studies (diabetes, stroke, 
cancer, chronic obstructive pulmonary disease, hypertension, 
coronary heart disease, chronic kidney disease, and heart 
failure). Fewer than half of studies included any one mental 
health condition, and one quarter of studies did not include any 
mental health condition.
Implications of all the available evidence
Multimorbidity has been increasingly researched in the past 
decade, but the literature is characterised by poor reporting and 
variation in the number and nature of conditions included in 
multimorbidity measurement. Reporting would be improved 
by studies clearly reporting which conditions they included in 
multimorbidity measurement and why conditions were chosen, 
and clinical code sets or clear definitions of how each individual 
condition was ascertained. A consensus is needed to establish a 
core condition set for multimorbidity that all studies should 
measure to facilitate comparison across studies, and guidance 
on principles for defining customised condition sets justified by 
purpose or context. Based on the present analysis, 
we recommend a potential core set of conditions to include in 
all measures, and other conditions that should be considered 
for inclusion deepening on context. Consensus studies are now 
needed to refine and inform this core set, to improve 
comparability and reproducibility of research in this field.
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nursing conditions. Qualitative research and case series 
were also excluded.
Search strategy and selection criteria 
The search strategy was developed in collaboration with a 
medical librarian (appendix p 3). Two sets of key terms 
(multimorbidity and measure) were combined with 
Boolean logic to search for relevant studies. Medical 
subject headings were used to capture concepts and 
maximise the number of studies retrieved. Searches were 
done in Ovid (PsycINFO, Embase, Global Health, and 
MEDLINE), Web of Science, the Cochrane Library, 
EBSCO (CINAHL Plus), Scopus, and ProQuest 
Dissertations & Theses Global, from inception to a last 
updated search on Jan 21, 2020. After the database 
searches, we hand­searched reference lists of retrieved 
articles and tracked citations.
Identified references were exported to EndNote 
(version X9) and Microsoft Excel 2016 for deduplication, 
and then imported to Covidence software for screening 
by two independent reviewers (IS­SH and PH) of titles, 
abstracts, and full­text articles against the eligibility 
criteria, with disagreement resolved by discussion and 
involvement of a third reviewer (BG) if necessary.
Data analysis 
Data on the characteristics of the included studies were 
extracted by a single reviewer (IS­SH) with predesigned 
data extraction tables. Data were extracted from published 
reports only; authors were not contacted. The extracted 
data included authors, year of publication, study title, study 
purpose, method, country, mean age of study participants, 
reference definition of multimorbidity, type of multi­
morbidity measure (simple counts or weighted indices), 
data collection method or data source (self­report, or 
medical records or administrative databases), number of 
conditions included in the multimorbidity measure, and 
the actual conditions included. Due to the wide variation in 
labelling of conditions included, we categorised similar 
conditions into groups. An example of how we categorised 
conditions is our category of chronic pain, for which 
one or more of the studies variously counted neck pain, 
back pain, low back pain, chronic low back pain, pain, 
chronic pain, painful conditions, trigeminal neuralgia, or 
fibromyalgia.
In relation to the first registered review objective 
examining how multimorbidity has been measured, we 
used descriptive analyses to summarise the characteristics 
of multimorbidity studies and measures. Categorical data 
on multimorbidity study characteristics are presented as 
counts and percentages. To further explore how the choice 
of multimorbidity measure (simple vs weighted counts) 
was related to study purpose, setting, and data source, we 
cross­tabulated measure type by these variables, with 
statistical significance tested by Pearson’s χ², considering 
a two­sided p value of 0·05 as the threshold for 
significance. If contingency table expected frequencies 
were less than 5, the p value was computed for a Monte 
Carlo test with 2000 duplicates.
In relation to the second registered review objective 
examining which conditions were included in multi­
morbidity measures, relationships between characteristics 
of multimorbidity studies and number of conditions 
included in the measure were examined with negative 
binomial generalised linear regression (the Poisson model 
was found to be overdispersed).16 The study characteristics 
examined as predictors were data source, study setting, 
study population, and type of measure used (dichotomised 
into simple count and weighted measure). Since data 
were missing on both outcome and predictors, multiple 
imputation with 100 imputed datasets and 20 iterations 
was done with Bayesian logistic regression for binary 
variables, and negative binomial regression for count 
data.17 Fraction of missing information (FMI) was 
computed to quantify loss of information due to missing 
status, and FMI was defined as small, moderate, or high 
as defined in White et al.18 The imputed dataset was 
then used for analysis, with statistical significance of 
associations assumed when the confidence interval did 
not include 1. Univariate models were initially fitted with 
negative binomial model coefficients exponentiated to 
estimated incidence rate ratios (IRRs), followed by 
multivariate models with examination of plausible 
interaction terms, and an interaction between type of 
measure and data source retained in the model.
The conditions included in different studies were 
examined after grouping by International Classification of 
Diseases­10 chapter, partially modified to reflect the 
organisation of clinical care (for example, throat disorders 
were grouped with ear disorders rather than digestive 
disorders), and examined in terms of individual conditions. 
To assess whether choice of condition varied by where the 
study was done, for each condition we cross­tabulated 
whether it was included in multimorbiditiy measurement 
with two variables: the continent where the study was 
done, and the income level of the country where the study 
was done (defined by the World Bank,19 and dichotomised 
into low­income and middle­income countries [LMICs] 
and high­income countries [HICs]). Statistical significance 
was examined with Pearson’s χ² test. For continent, which 
has six categories, when χ² test indicated significant 
associations (at p<0·05), post­hoc analysis was done to 
identify which continent was significantly associated with 
inclusion of that condition.20 To contextualise the observed 
choices of conditions in the reviewed studies, we extracted 
data on the burden of disability­adjusted life years (DALYs) 
and years of life lost (YLLs) from the Global Burden of 
Disease Study 2019 for the 44 chronic conditions with the 
highest DALY burden,21 and examined how often these 
conditions were included in multimorbidity measurement. 
The Effective Public Health Practice Project (EPHPP) 
quality assessment tool for quantitative studies was used to 
assess risk of bias and quality of the included studies.22 
The EPHPP tool evaluates selection bias, study design, 
For the Covidence software 
platform see https://www.
covidence.org/
See Online for appendix
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confounders, blinding, data collection method, and 
withdrawals and dropouts. We also evaluated two other 
types of bias: publication bias (for which high risk of bias 
was judged present if the same data were reported variably 
in different papers), and conflict of interest (for which risk 
of bias was rated unclear if no conflict of interest statement 
was present). Each domain was rated as low, moderate, 
high, or unclear risk of bias. The overall risk of bias for 
each study was classed as low, moderate, or high based on 
the most frequent component score. We also categorised 
each study in terms of clarity of reporting of multi­ 
morbidity measurement and definition. Clear reporting of 
multi morbidity was judged to be present if a study had 
reported the reference definition for measuring multi­
morbidity and listed all health conditions included in the 
multimorbidity measure. Associations between overall 
risk of bias and clarity of reporting were examined post hoc 
with cross­tabulation and Pearson χ² test.
All statistical tests were done with R (version 4.0.1).
Where quanti tative analyses were not suitable, a narrative 
overview was given.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, writing of 
the report, or the decision to submit for publication.
Results 
We identified 13 807 articles from our database search. 
Study selection and reasons for exclusion are summarised 
in figure 1. Overall, 566 studies were included in our 
systematic review (table 1, appendix pp 5–71). Most studies 
were done in Europe (209 [36·9%]), followed by North 
America (190 [33·6%]). The majority of studies were 
community­based (320 [56·5%]) or primary care­based 
(126 [22·3%]). Data on multimorbidity were mainly 
collected by patient self­report (312 [55·1%] studies) 
or medical records and administrative databases 
(240 [42·4%]). Eight (1·4%) studies did not report data 
source. Of 525 studies that examined a single measure of 
multimorbidity, 73 (13·9%) had incomplete reporting, 
with missing status highest for the count variable of 
number of conditions included in the multimorbidity 
measure (56  [10·7%] studies), and the binary variables of 
measure type (28 [5·3%] studies; with those including 
more than one measure type treated as missing]), and 
data source (eight [1·5%] studies).
The most common stated purposes of measuring multi­
morbidity in the included studies were examination of its 
association with various outcomes (209 [36·9%] studies) 
and examination of measure performance (117 [20·7%]). 
Other purposes were identification of multi morbidity 
patterns (62 [11·0%]) and examination of multimorbidity 
trajectories over time (19 [3·4%]; table 1, appendix pp 5–71). 
Multimorbidity was most commonly examined in studies 
of adults of any age (240 [42·4%]), in studies of older 
adults (216 [38·2%]), and in studies of middle­aged and 
older adults (80 [14·1%]; table 1, appendix pp 5–71).
Almost half of the studies (268 [47·3%]) defined 
multimorbidity as the presence of two or more chronic 
conditions, with other studies defining multimorbidity 
as multiple chronic conditions (56 [9·9%]), three or 
more chronic conditions (28 [4·9%]), or five or more 
chronic conditions (four [0·7%]). 206 (36·4%) studies 
did not report a reference definition (table 1, 
appendix pp 5–71). Three studies defined severe or 
complex multimorbidity (according to various terms) in 
addition to overall multi morbidity, with the cutoff point 
for severe defined as four or more chronic conditions in 
Figure 1: Study selection for systematic review
19 095 studies identified from database searches 
 6834 in MEDLINE
 6836 in Embase
 1978 in PsycINFO
 1022 in Scopus
 241 in Web of Science
 484 in Global Health
 1616 in CINAHL Plus
 60 in Cochrane Library
 24 in ProQuest Dissertations & Theses Global
 
13 807 screened (title and abstract)  
915 screened (full text)
549 included for the review
5288 duplicates removed
12 892 excluded (not relevant to multimorbidity 
               or multiple chronic conditions; had a study 
               population with an index condition 
               relevant to multiple sclerosis [due to the 
               search term “multiple chronic conditions”]; 
               or studying a comorbidity of a specific 
               condition)
366 excluded
 19 not in English
 5 duplicates
 160 full text unavailable
 41 with an index condition (including 
pregnancy)
 1 with nursing diagnoses
 17 review articles
 11 based on acute conditions or critically 
ill patients
 9 based on qualitative research
 103 not measuring multimorbidity
17 studies identified by reference searching, citation 
tracking, and updated database searching (last 
updated Jan 21, 2020)
566 included in the final review
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two studies23,24 and five or more chronic conditions in 
one study.25
376 (66·4%) studies used a simple count of conditions 
to measure multimorbidity, 155 (27·4%) used weighted 
indices, 27 (4·8%) used both types of measures together, 
and eight (1·4%) did not report the type of measure 
used (table 1, appendix pp 5–71). In studies that used 
a weighted index, 149 used a disease­based index, and 
six used a medication­based index. The most commonly 
used disease­based indices were various versions of 
the Charlson comorbidity index (CCI; 64 studies) and 
the cumu lative illness rating scale­geriatric (CIRS­G; 
25 studies). Medication­based indices comprised the 
chronic disease score (two studies26,27), the Rx­risk comor­
bidity index (two studies28,29), the medication­based disease 
burden index (MDBI; one study30), and a medicines 
comorbidity index (one study31). Common weighting 
methods for indices were: use of regression models to 
calculate weights for each condition on the basis of associ­
ation with a particular outcome (eg, the CCI); rating of 
condition severity on the basis of prespecified thresholds 
of severity (eg, the CIRS­G32 and the weighted index 
developed by Bayliss and colleagues33); and assignment of 
weights on the basis of existing disease burden literature 
(eg, the MDBI30).
Weighted multimorbidity measures were marginally 
more likely to be used in studies collecting data from 
medical records or administrative databases (118 [53·9%] 
of 219 studies with non­missing data for type of multi­
morbidity measure), whereas simple counts of conditions 
were more commonly used in studies that were based on 
self­report data (271 [88·6%] of 306 studies; χ²=109·33, 
p<0·0001; appendix p 72). The choice of measure varied 
depending on study purpose, with weighted mea­
sures primarily used to examine measure performance 
(92 [84·4%] of 109 studies), whereas simple counts were 
more commonly used for all other purposes (χ²=208·22, 
p=0·0005). Similarly, the choice of measure varied by 
study setting, with simple counts more commonly used in 




Primary care 126 (22·3%)
Hospital 104 (18·4%)
Care home 14 (2·5%)
Primary care and hospitals 2 (0·4%)
Data source
Patient self-report or interviews 312 (55·1%)
Medical records and administrative databases 240 (42·4%)
Patient self-report plus medical records and 
administrative databases
6 (1·1%)
Not reported* 8 (1·4%)
Study population†
All adults (age ≥15 years) 240 (42·4%)
Only children (age <18 years) 5 (0·9%)
Young and middle-aged adults (age 18–64 years) 10 (1·8%)
Middle-aged adults (age 40–65 years) 8 (1·4%)
Middle-aged and older adults (age ≥40 years) 80 (14·1%)
Older adults (age ≥60 years) 216 (38·2%)
All ages 7 (1·2%)
Primary study purpose
Association of multimorbidity with outcome 209 (36·9%)
Association of risk factors with multimorbidity 75 (13·3%)
Patterns or clusters of multimorbidity diseases 62 (11·0%)
Trajectory of multimorbidity 19 (3·4%)
Examination of multimorbidity measure 
performance‡
117 (20·7%)
Study of populations with multimorbidity 68 (12·0%)
Prevalence or burden of multimorbidity 16 (2·8%)
Definition (threshold) for multimorbidity
Not reported 206 (36·4%)
Two or more chronic conditions 268 (47·3%)
Three or more chronic conditions 28 (4·9%)
Five or more chronic conditions 4 (0·7%)
Multiple chronic conditions§ 56 (9·9%)
Patient-defined weighted cumulative score 4 (0·7%)
(Table 1 continues in next column)
Number of studies 
(n=566)
(Continued from previous column)
Type of multimorbidity measure
Simple count 376 (66·4%)
Weighted index of conditions 149 (26·3%)
Weighted index of medications 6 (1·1%)
Both simple count and weighted index 27 (4·8%)
Unclear¶ 8 (1·4%)
Number of conditions included in measure







Not applicable (studies that examined multiple 
measures)
41 (7·2%)
Percentages might not add to 100% due to rounding. Complete definitions of 
variables and age groups across individual studies are provided in the appendix 
(p 4). *None of the studies reported a reason for not reporting data source. 
†Population age ranges were according to individual study definitions (appendix 
p 4). ‡Studies that examined the performance of multimorbidity measures 
(including development, validation, or adaptation); compared the predictive 
performance for different measures in relation to outcomes; examined different 
multimorbidity definitions and how these affected estimates of multimorbidity 
prevalence; or examined the difference in measure performance between 
self-report and medical records or administrative databases. §Implicitly two or 
more chronic conditions, but not stated numerically. ¶The same eight studies 
that did not report data source.
Table 1: Study characteristics
Articles
6 www.thelancet.com/public-health   Published online June 21, 2021   https://doi.org/10.1016/S2468-2667(21)00107-9
community settings (269 [85·9%] of 313 studies) and 
primary care (81 [73·6%] of 110 studies), whereas weighted 
measures were predominantly used in hospital settings 
(73 [77·7%] of 94 studies; χ²=147·66, p=0·0005).
56 (9·9%) of the 566 studies did not report how many 
chronic conditions were included in their multimorbidity 
measure, and 41 (7·2%) compared the performance of 
multiple measures in relation to outcomes (table 1, 
appendix pp 5–71). For the 469 (82·9%) remaining studies 
examining a single measure, the number of con ditions 
included in the measure ranged from two to 285 
(median 17 [IQR 11–23]; appendix p 73).
Associations between multimorbidity study character­
istics and the number of conditions included in measures 
of multimorbidity are shown in table 2. In univariate 
analysis, studies measuring multimorbidity on the basis of 
database sources included more conditions in measures of 
multi morbidity than studies based on patient self­report, 
and community­based studies included fewer conditions 
in measures of multimorbidity than studies in primary 
care, hospital, and care home settings. Studies that 
included older adults included more conditions in mea­
sures of multimorbidity than those restricted to children 
or younger and middle­aged adults. In the multivari ate 
model, studies of database sources were estimated to 
include more than twice as many conditions in measures 
of multimorbidity than self­report studies (IRR 2·2 
[95% CI 1·8–2·6]). Study setting and study population 
were not significantly associated with the number of 
conditions included in measures in the adjusted model. 
With the exception of five studies measuring multi­
morbidity in children in which FMI was 0·53 (high), FMI 
ranged from 0·04–0·30 (small to moderate) indicating that 
multiple imputation uncertainty was acceptable.
73 (12·9%) of the 566 studies did not report which 
health conditions were included in their measure, and 
41 (7·2%) compared the predictive performance of 
multiple measures. In the remaining 452 (79·9%) studies, 
67 conditions were included across the individual study 
measures of multimorbidity. Most of the 452 studies 
included at least one cardiovascular condition (441 [97·6%] 
studies), metabolic and endocrine con di tion (440 [97·3%]), 
respiratory condition (422 [93·4%]), musculoskeletal 
condition (396 [87·6%]), or mental health condition 
(355 [78·5%]) in the measure of multimorbidity used 
(figure 2). Conversely, chronic infections (123 [27·2%] 
studies), haematological conditions (110 [24·3%]), ear, 
nose, and throat conditions (107 [23·7%]), skin conditions 
(70 [15·5%]), oral conditions (19 [4·2%]), and congenital 
conditions (14 [3·1%]) were included in the morbidity 
measure by a minority of studies.
With respect to individual health conditions (appendix 
p 74), only eight conditions were included by more than 
half of studies in the multimorbidity measure used. 
Diabetes was included in 411 (90·9%) of 452 studies, with 
fewer studies including stroke (357 [79·0%]), cancer 
(349 [77·2%]), chronic obstructive pulmonary disease 
(322 [71·2%]), hypertension (316 [69·9%]), coronary heart 
disease (275 [60·8%]), chronic renal disease (240 [53·1%]), 
and heart failure (230 [50·9%]) in the multimorbidity 
measure. By contrast, health conditions included in less 
than 2% of studies were sleep apnoea (five [1·1%]), chronic 
fatigue syndrome (four [0·9%]), and attention deficit 
hyperactivity disorder (three [0·7%]).
Fewer than half of studies included any one mental 
health condition in their multimorbidity measure. 
Multimorbidity measures included both physical and 
mental health conditions in 331 (73·2%) studies, 
exclusively physical conditions in 115 (25·4%) studies, 
and exclusively mental health conditions in six (1·3%) 
studies. In studies including both physical and mental 
health conditions, measures usually only included a 
small number of mental health conditions. In all studies, 
the most commonly included mental health condi­
tions were depression (219 [48·5%] studies), dementia 
(197 [43·6%]), and anxiety (98 [21·7%]). All other mental 
health conditions, including schizo phrenia, alcohol and 
drug use disorders, and bipolar disorder, were included 
in less than 20% of studies.
Inclusion of a condition had no significant association 
with country level of income or continent of study, except 
for tuberculosis, on Pearson’s χ²  tests (data not shown). 
In our post­hoc analysis, we found that 23 (6·2%) of 






Fraction of missing 
information
Data source
Patient self-report 16 (11) 1 (ref) 1 (ref) 1 (ref)
Databases 32 (41) 1·8 (1·6–2·0)* 2·2 (1·8–2·6)* 0·12
Setting
Community 19 (20) 1 (ref) 1 (ref) 1 (ref)
Primary care 26 (27) 1·3 (1·1–1·5)* 0·9 (0·8–1·1) 0·11
Hospital 27 (34) 1·5 (1·2–1·7)* 1·1 (0·9–1·3) 0·10
Care home 43 (77) 2·3 (1·5–3·4)* 1·4 (1·0–2·2)* 0·16
Population
All adults 25 (32) 1 (ref) 1 (ref) 1 (ref)
Only children 6 (1) 0·3 (0·1–0·9)* 0·4 (0·1–1·1) 0·53
Young and middle-aged 
adults
12 (4) 0·5 (0·3–0·9)* 0·6 (0·4–1·0) 0·19
Middle-aged adults 14 (11) 0·6 (0·3–1·2) 0·6 (0·3–1·0) 0·30
Middle-aged and older 
adults
24 (40) 0·9 (0·8–1·2) 1·0 (0·9–1·2) 0·07
Older adults 19 (12) 0·8 (0·7–0·9)* 0·9 (0·7–1·0) 0·11
All ages 28 (11) 1·2 (0·7–2·0) 1·3 (0·8–2·1) 0·09
Type of measure
Simple count 21 (30) 1 (ref) 1 (ref) 1 (ref)




NA NA 0·4 (0·3–0·5)* 0·09
IRR=incidence rate ratio. NA=not applicable. *p<0·05.
Table 2: Association between number of conditions included in the multimorbidity measure and study 
characteristics
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371 studies in HICs included tuberculosis in their 
multimor bidity measurement, compared with 11 (16·4%) 
of 67 studies in LMICs (χ²=6·91, p=0·0009; appendix 
p 75). By continent, significant associ ations were 
observed regarding inclusion of tuberculosis in the 
multimorbidity measurement, with our post­hoc test 
identifying Asia as having a significantly higher 
proportion of studies including tuberculosis (14 [20·6%] 
of 68 studies) than Europe (eight [4·9%] of 163 studies), 
North America (five [3·3%] of 150 studies), Australasia 
(five [15·6%] of 32 studies), Africa (one [33·3%] of 
three studies), and South America (one [4·5%] of 
22 studies; χ²=27·42, p=0·0002; appendix p 75).
We analysed how often conditions with the highest 
global burden of DALYs and YLLs in the Global Burden of 
Disease Study 201921 were included in multimorbidity 
measures among the 452 studies that specified chronic 
conditions (figure 3, appendix p 76). Of the 10 conditions 
with highest DALY burden, coverage in multimorbidity 
mea sures ranged from 12 (2·7%) studies to 411 (90·9%) 
studies. Among the 25 conditions with highest DALY 
burden, conditions included in less than 10% of multi­
morbidity measures were tuberculosis, malnutrition, 
gynaecological disorders, and oral disorders.
Of the 566 studies measuring multimorbidity, 107 were 
rated to be at high risk of bias, 419 at moderate risk of bias, 
and 40 at low risk of bias (appendix pp 77–118). In our 
post­hoc analysis, risk of bias was significantly associated 
with clarity of reporting of multimorbidity measurement; 
studies at low risk of bias were significantly less likely to 
have unclear reporting (four [10·0%] of 40 studies) than 
studies with moderate risk of bias (101 [24·1%] of 
419 studies) and high risk of bias (82 [76·6%] of 
107 studies; (χ²=116·64, p<0·0001; appendix p 119).
Discussion 
In this review, more than a third of studies did not report 
their definition of multimorbidity. When reported, the 
most common definition used was two or more chronic 
conditions, with small numbers of studies using three or 
more conditions or five or more conditions as cutoffs. 
One in ten studies did not report the number of 
conditions included in the multimorbidity measure, and 
one in eight did not report which conditions were 
included. The number of conditions included in 
multimorbidity measures showed large variation, 
ranging from two to 285 (median 17 [IQR 11–23]). 
Approximately 66% of studies used a simple count for 
multimorbidity measure ment (for a range of study 
purposes), whereas nearly 30% of studies measured 
multimorbidity with weighted indices (mainly for 
predicting outcomes).
The 452 studies which reported the conditions 
included in their multimorbidity measure varied in 
terms of which conditions they counted. More than 
90% of studies included at least one cardiovascular, 
metabolic and endocrine, or respiratory condition. 
Figure 2: Long-term conditions included in multimorbidity measures
Conditions were grouped according to ICD-10 chapter with modification to reflect the organisation of clinical care. 
The 67 conditions are shown in descending order in the appendix (p 74). ICD= International Classification of 
Diseases. *Due to injury. †Sleep apnoea is classed as a nervous system disorder in ICD-10. ‡Learning disabilities 
include congenital conditions in which learning disability is a dominant feature (eg, Down syndrome). §Chronic 
pain and chronic fatigue syndrome are classed as symptoms or signs in ICD-10. ¶Throat conditions are classed as 
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Chronic infections, haema tological conditions, ear, nose, 
and throat condi tions, skin conditions, oral conditions, 
and congenital conditions were included by less than a 
third of studies. Only eight individual conditions were 
included by more than half of studies in the measure of 
multimorbidity used, all of which were physical health 
conditions (dia betes, stroke, malignancy, hypertension, 
chronic obstruc tive pulmonary disease, coronary heart 
disease, chronic renal disease, and heart failure).
Fewer than half of studies included any one mental 
health condition, and a quarter of studies did 
not include any mental health condition, which identi­
fies a clear gap in the literature. Mental and physical 
multimorbidity has been well recognised to have collective 
effects on mortality, quality of life, disability, and patient 
activation in managing their own health care.34–36 
Therefore, the inclusion of mental health conditions, such 
as depression, dementia, anxiety, and schizophrenia is 
Figure 3: DALYs of selected conditions and percentage of studies including each condition in multimorbidity measurement
Conditions are ranked in descending order of attributable DALYs from the Global Burden of Disease Study 2019; data on DALYs were derived from the supplementary appendixes of Vos et al21 
(appendix p 75). DALYs comprise the estimates of years of life lost due to premature mortality and years lived with disability. DALYs=disability-adjusted life years. *Conditions relating to consequences 
of injury in this study are paralysis (from causes other than stroke; 75 [16·6%] of 452 studies) and long-term musculoskeletal impairment due to injury (47 [10·4%]).
0 25 50 75 100
Studies including condition in multimorbidity measurement
(%; n=452)
3500 3000 10002500 2000 1500 500 0






























Upper digestive tract disease
Anaemia
Epilepsy














www.thelancet.com/public-health   Published online June 21, 2021   https://doi.org/10.1016/S2468-2667(21)00107-9 9
required to properly understand the epidemiology and 
implications of multimorbidity.
Previous narrative systematic reviews on multimorbidity 
measurement have focused on the comparison of different 
weighted indices in predicting one or more outcomes, 
including mortality and health care utilisation.10,37–39 
Consistent with previous reviews,13,39 in this review we 
found that studies commonly used a weighted index when 
the purpose was to predict outcomes, and Stirland and 
colleagues39 in their recent systematic review provided 
recommendations on which weighted index to use for a 
particular outcome of interest. Although simple counts 
with a cutoff of two or more conditions to define 
multimorbidity are commonly used,40 this approach has 
been criticised as being unable to identify people with the 
greatest needs.41 However, in practice the predictive 
validity of weighted indices and a simple count often only 
differs slightly.42,43 Beyond counting, a shift of focus has 
been suggested in recent years to improve understanding 
of the effects of particular disease clusters on clinical 
outcomes.2,44
We identified that a notable minority of studies did 
not report how multimorbidity was defined and 
measured. At a minimum, we believe that all studies of 
multimorbidity need to clearly report: their core 
multimorbidity definition, and whether measured by a 
simple count or a weighted index; which conditions are 
included in the measure; why these conditions were 
selected in relation to the purpose of the study; and how 
each condition has been defined including any clinical 
code sets used.
Clear reporting is essential, but our study also found 
large variation in the number and nature of the 
conditions included in multimorbidity measures. The 
optimal conditions to include are likely to vary somewhat 
by study context and purpose, but we believe there is 
value in identifying a core set of conditions that all 
studies should include, and factors which might then 
influence choice of other conditions. We recognise that 
no reason exists in principle to exclude any condition 
from morbidity counts, and that rare diseases are 
cumulatively common, but identifying rare conditions 
in routine data is problematic, and self­report studies 
are limited by concerns for participant burden when 
completing surveys, often leading to the use of general 
condition categories for participants to choose from.45 
Similarly, uncertainty exists about when to count 
condition subgroups separately (eg, myocardial infarc­
tion or angina) or within more heterogenous groups 
(eg, coronary artery disease). The 67 conditions we 
identified across 452 studies that reported type of 
conditions provide insight and, along with consideration 
of conditions with high DALYs or YLL, provide a 
potential core list to choose from, but we recognise that 
researchers might deviate from such a list depending on 
their pur pose. Based on our analysis of conditions most 
commonly included in multimorbidity measures, and 
drawing on the recommendations of a previous review10 
and DALY burden of different conditions,21 we propose a 
minimal core list of 20 conditions and considerations 
for choosing other conditions (figure 4), although 
consensus studies are needed to refine choices, and to 
underpin further research that is comparable and 
reproducible.
The key strengths of this review include comprehensive 
database searches, assessment of risk of bias, robust 
analysis, and the systematic examination of multi­
morbidity measurement in a large number of studies. A 
limitation is inconsistency in the labelling of relevant 
studies, meaning that not all relevant studies are likely 
to have been included, although we assume this had 
little effect on the overall conclusion that multimorbidity 
measurement is poorly reported and highly variable. 
There was also considerable variation in how different 
conditions were named or grouped by multimorbidity 
measures, which meant that for synthesis we had to 
group or combine some conditions that the underlying 
studies kept distinct. Restricting included studies to 
English might also mean that we have missed relevant 
studies in other countries, particularly low­income and 
middle­income countries. The possible consequence is 
that true heterogeneity of measurement is larger than 
we observed.
To conclude, this review found that many previous 
studies have not clearly reported their methods of measur­
ing multimorbidity. Consistent reporting of measure 
definitions and condition definitions is required. When 
reported, measurement of multimorbidity was highly 
variable. A consensus is needed to establish a core 
condition set that all studies should measure (to facilitate 
comparison and synthesis across studies), and study 
purposes and contexts for which other condition sets will 
be appropriate.
Figure 4: A potential core list of 20 chronic conditions to include in measures of multimorbidity and 
considerations for choosing other conditions
 (1) Cancer
 (2) Coronary heart disease
 (3) Stroke






 (10) Alcohol use disorders
 (11) Drug use disorders
 (12) Chronic liver disease
 (13) Chronic renal disease
 (14) Chronic obstructive pulmonary disease
 (15) Asthma
 (16) Vision impairment
 (17) Musculoskeletal impairment due to injury
 (18) Osteoarthritis
 (19) Chronic pain
 (20) Gynaecological disorders
Potential core conditions with high disability-
adjusted life-years or high years of life lost
Potential considerations for including other 
conditions
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• Congenital disease
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• More detailed condition definition might be 
relevant (eg, myocardial infarction or stable angina)
• Inclusion of rare conditions might be appropriate
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